Mirae Asset Global Investments Co. Ltd. Makes New $149,000 Investment in Perrigo Company plc (NYSE:PRGO)

Mirae Asset Global Investments Co. Ltd. acquired a new position in Perrigo Company plc (NYSE:PRGO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,900 shares of the company’s stock, valued at approximately $149,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in Perrigo by 229.2% in the 3rd quarter. Wellington Management Group LLP now owns 2,697,698 shares of the company’s stock worth $70,761,000 after buying an additional 1,878,145 shares during the period. FMR LLC boosted its holdings in shares of Perrigo by 66,795.3% in the 3rd quarter. FMR LLC now owns 1,840,289 shares of the company’s stock valued at $48,271,000 after acquiring an additional 1,837,538 shares during the last quarter. Copeland Capital Management LLC increased its stake in shares of Perrigo by 23.1% in the third quarter. Copeland Capital Management LLC now owns 2,482,544 shares of the company’s stock worth $65,117,000 after acquiring an additional 465,161 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Perrigo by 58.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,039,702 shares of the company’s stock worth $27,271,000 after purchasing an additional 383,728 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Perrigo during the third quarter valued at $8,892,000. Institutional investors and hedge funds own 95.91% of the company’s stock.

Insider Buying and Selling

In related news, Director Jeffrey B. Kindler sold 17,598 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $28.27, for a total value of $497,495.46. Following the completion of the sale, the director now owns 5,409 shares of the company’s stock, valued at approximately $152,912.43. The trade was a 76.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

PRGO has been the topic of several analyst reports. StockNews.com raised Perrigo from a “hold” rating to a “buy” rating in a research report on Monday. Argus lowered Perrigo from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. Finally, Piper Sandler downgraded Perrigo from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $34.00 to $27.00 in a report on Monday, January 6th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Perrigo Trading Up 2.0 %

PRGO stock opened at $24.80 on Friday. Perrigo Company plc has a 52-week low of $23.14 and a 52-week high of $33.46. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94. The firm has a market cap of $3.38 billion, a P/E ratio of -21.19 and a beta of 0.54. The company’s 50-day simple moving average is $25.32 and its 200-day simple moving average is $26.40.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.